212
Kronik HCV
23.
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M et al.
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New
Engl J Med 2014; 370(17): 1604–1614.
24.
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al. ABT-450/r-
ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. New Engl J
Med 2014; 370:1973–1982.
25.
Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y et al. Turquoise-
III: Safety and efficacy of 12-week ribavirin-free treatment for patients with HCV
genotype 1b and cirrhosis. 15th International Symposium on Viral Hepatitis and
Liver Disease, Berlin, Germany, 26 June 2015.
26.
Eron JJ, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, et al. Safety and efficacy
of ombitasvir–450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients
receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc 2014;17(4 Suppl
3):19500.
27.
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al. An
interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med
2014;371:2375-82.
28.
Lok AS, Gardiner DF, Hézode C, Lawitz EJ, Bourlière M, Everson GT, et al.
Randomized trial of daklatasvir and asunaprevir with or without PegIFN/RBV for
hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-9.
29.
Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E,Bourlière M et
al. Efficacy of an interferon and ribavirin-free regimen of daklatasvir, asunaprevir,
and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Gastroenterology 2014;146:420–429.
30.
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY et al. All-oral
daklatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational,
phase 3, multicohort study. Lancet 2014;384:1597-605.
31.
Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, et al. Fixed-dose
combination therapy with daklatasvir, asunaprevir, and beklabuvir for noncirrhotic
patients with HCV genotype 1 infection. JAMA 2015;313:1728-35.
32.
Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, et al. Daklatasvir
in combination with asunaprevir and beklabuvir for hepatitis C virus genotype 1
infection with compensated cirrhosis. JAMA 2015;313:1736-44.
33.
Zeuzem S, Ghalip R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y et al. Grazoprevir-
Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic
Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A
Randomized Trial. Ann Intern Med 2015;163:1-13.
34.
Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir/
Elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of
combination therapy containing a direct-acting antiviral agent. J Hepatol 2015. pii:
S0168-8278(15)00291-3. doi:10.1016/j.jhep.2015.04.009.
35.
Roth D, Nelson D, Bruchfeld A, Liapakis AM, Silva M, Monsour H et al. C-SURFER:
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients
with hepatitis C virus genotype 1 infection and chronic kidney disease. 50th The
International Liver Congress 2015, Apr 22-26, Vienna Austria.
36.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-
5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype
1 infection in previously untreated patients with cirrhosis and patients with previous
null response with or without cirrhosis (C-WORTHY): a randomised, open-label
